Durability of response to icotrokinra for high‐impact site psoriasis: 1‐year ICONIC ‐ TOTAL findings
Journal of the European Academy of Dermatology and Venereology · 2026-09 · 40 (9) · 1502-1514
DOI: 10.1111/jdv.70471 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 23.05.2026. Verfasst von Richard B Warren und 15 weiteren Autor:innen. Beteiligte Einrichtung: Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Dermatology Centre, Manchester NIHR Biomedical…. Hauptthemen laut MEDLINE: Psoriasis, Peptides, Cyclic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson, Johnson and Johnson.
Abstract (Originalsprache)
Background
High‐impact site plaque psoriasis is difficult to treat. Icotrokinra, an oral peptide with high specificity for the interleukin (IL)‐23 receptor, demonstrated significantly higher rates of high‐impact site psoriasis clearance, versus placebo, with no safety signals, through Week (W)16.
Objectives
Report clinical response rates and safety through 1 year of icotrokinra treatment in participants with high‐impact site plaque psoriasis.
Methods
Participants (≥12 years of age; psoriasis body surface area ≥1%; Investigator's Global Assessment [IGA] ≥2) with at least moderate scalp, genital or hand/foot psoriasis were randomized (2:1) to once‐daily icotrokinra 200 mg ( N = 208) or placebo ( N = 103), with placebo‐to‐icotrokinra transition at W16 ( N = 92). Rates (using nonresponder imputation) of achieving clear/almost clear (0/1) or clear (0) overall skin (IGA), genital (static Physician's Global Assessment of genitalia [sPGA‐G]), hand/foot (hf‐PGA) psoriasis and absent/very mild (0/1) or absent (0) scalp psoriasis (scalp‐specific‐IGA [ss‐IGA]), modified Nail Psoriasis Severity Index (mNAPSI) percent improvement and safety were assessed through W52.
Results
Eighty‐eight per cent (275/311) of participants completed treatment through W52. In icotrokinra‐randomized participants, response rates increased through W24 and were durable through W52 for overall psoriasis clearance (IGA 0/1 range: 67%–70%) and across high‐impact sites (ss‐IGA 0/1: 72%–78%; sPGA‐G 0/1: 85%–90%; hf‐PGA 0/1: 54%–62%); responses were consistent among placebo‐randomized participants after transitioning to icotrokinra. High proportions of icotrokinra‐randomized participants achieved complete clearance during W24–52 (IGA 0: 44%–51%; ss‐IGA 0: 57%–66%; sPGA‐G 0: 73%–84%; hf‐PGA 0: 44%–58%). Mean mNAPSI improvement increased from W16 (33%) to W52 (62%). Exposure‐adjusted rates of participants with ≥1 adverse event (AE) or serious AE through W16 were similar between icotrokinra and placebo, with no increase in AE rates or occurrence of a safety signal through W52.
Conclusions
Icotrokinra demonstrated high and durable rates of psoriasis clearance across high‐impact sites, with a favourable safety profile, through 1 year.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Dermatology Centre, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, Universit…
- SKiN Centre for Dermatology, Peterborough, Ontario, Canada.
- Department of Medicine, Queen's University, Kingston, Ontario, Canada.
- Probity Medical Research, Waterloo, Ontario, Canada.
- Austin Institute for Clinical Research, Sanova Dermatology, Austin, Texas, USA.
- Innovaderm Research, Montreal, Quebec, Canada.
ORCID-Profile: Melinda Gooderham, Robert Bissonnette, Julien Ringuet, Andreas Pinter, Jessica H Rubens
Förderung
- Johnson & Johnson
- Johnson and Johnson
Zitieren
APA
Warren, R. B., Gooderham, M., Lain, E., Bissonnette, R., Huang, Y. H., Ringuet, J., Hoffmann, M., Pinter, A., Merola, J. F., Rubens, J. H., Fan, D., Hsu, M. C., Li, S., Yang, Y. W., DeKlotz, C. M. C., & Song, E. J. (2026). Durability of response to icotrokinra for high‐impact site psoriasis: 1‐year ICONIC ‐ TOTAL findings. Journal of the European Academy of Dermatology and Venereology, 40(9), 1502-1514. https://doi.org/10.1111/jdv.70471
Vancouver
Warren RB, Gooderham M, Lain E, Bissonnette R, Huang YH, Ringuet J, et al. Durability of response to icotrokinra for high‐impact site psoriasis: 1‐year ICONIC ‐ TOTAL findings. Journal of the European Academy of Dermatology and Venereology. 2026;40(9):1502-1514. doi:10.1111/jdv.70471
BibTeX
@article{Warren2026,
author = {Warren, Richard B and Gooderham, Melinda and Lain, Edward and Bissonnette, Robert and Huang, Yu-Huei and Ringuet, Julien and Hoffmann, Matthias and Pinter, Andreas and Merola, Joseph F and Rubens, Jessica H and Fan, Dorothy and Hsu, Ming-Chun and Li, Shu and Yang, Ya-Wen and DeKlotz, Cynthia M C and Song, Eingun James},
title = {Durability of response to icotrokinra for high‐impact site psoriasis: 1‐year ICONIC ‐ TOTAL findings},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
volume = {40},
number = {9},
pages = {1502--1514},
doi = {10.1111/jdv.70471}
}
EUVIMED